Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2026

Conditions
Acute Myeloid LeukemiaLeukemia, Acute MyeloidMyeloid Leukemia, AcuteLeukemia, Myeloid, AcuteAcute Myelogenous LeukemiaLeukemia, Acute MyelogenousMyelogenous Leukemia, AcuteAMLBone Marrow Transplant
Interventions
DRUG

Iomab-B

DRUG

Conventional Care

PROCEDURE

HCT

Trial Locations (24)

10022

Weill Cornell Medicine, New York

10038

Memorial Sloan Kettering Cancer Center, New York

11794

Stony Brook University, Stony Brook

14263

Roswell Park Cancer Institute, Buffalo

20007

Georgetown University Medical Center, Washington D.C.

27599

University of North Carolina Hospital, Chapel Hill

32224

Mayo Clinic, Jacksonville

43210

The Ohio State University Comprehensive Cancer Center, Columbus

44106

University Hospital of Cleveland Seidman Cancer Center, Cleveland

52242

University of Iowa, Iowa City

53226

Medical College of Wisconsin, Milwaukee

55902

Mayo Clinic, Rochester

60153

Loyola University Medical Center, Maywood

63110

Washington University School of Medicine, St Louis

66205

The University of Kansas Cancer Center, Westwood

68106

University of Nebraska Medical Center, Omaha

75246

Baylor Charles A. Sammons Cancer Center, Dallas

77030

MD Anderson Cancer Center, Houston

85234

Banner MD Anderson Cancer Center, Gilbert

97239

Oregon Health & Science University, Portland

98109

Fred Hutchinson Cancer Research Center, Seattle

06520

Yale Cancer Center, New Haven

Unknown

University of Ottawa, Ottawa

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors
All Listed Sponsors
lead

Actinium Pharmaceuticals

INDUSTRY